Genmab and argenx enter partnership to advance antibody therapies in immunology and oncology

Media release copenhagen, denmark; april 1 7 , 2023 genmab and  argenx   have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies discovery programs against two differentiated targets are underway    genmab a/s  (nasdaq: gmab) and argenx  (euronext & nasdaq: argx) announced today that genmab and  argenx  have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology , as well as i n oncology therapeutic areas. the multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address unmet patient needs in immunology and cancer.
ARGX Ratings Summary
ARGX Quant Ranking